- Home
- OPY vs ABUS Comparison
OPY vs ABUS Comparison
Compare OPY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- ABUS
- Stock Information
- Founded
- OPY 1881
- ABUS 2005
- Country
- OPY United States
- ABUS United States
- Employees
- OPY N/A
- ABUS N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- ABUS Health Care
- Exchange
- OPY Nasdaq
- ABUS Nasdaq
- Market Cap
- OPY 599.0M
- ABUS 592.8M
- IPO Year
- OPY N/A
- ABUS N/A
- Fundamental
- Price
- OPY $60.93
- ABUS $3.30
- Analyst Decision
- OPY
- ABUS Strong Buy
- Analyst Count
- OPY 0
- ABUS 4
- Target Price
- OPY N/A
- ABUS $5.50
- AVG Volume (30 Days)
- OPY 47.9K
- ABUS 912.9K
- Earning Date
- OPY 04-25-2025
- ABUS 05-20-2025
- Dividend Yield
- OPY 1.19%
- ABUS N/A
- EPS Growth
- OPY 84.56
- ABUS N/A
- EPS
- OPY 6.74
- ABUS N/A
- Revenue
- OPY $1,358,354,000.00
- ABUS $6,171,000.00
- Revenue This Year
- OPY N/A
- ABUS $14.57
- Revenue Next Year
- OPY N/A
- ABUS $15.84
- P/E Ratio
- OPY $8.89
- ABUS N/A
- Revenue Growth
- OPY 12.80
- ABUS N/A
- 52 Week Low
- OPY $41.24
- ABUS $2.63
- 52 Week High
- OPY $73.12
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- OPY 58.34
- ABUS 48.30
- Support Level
- OPY $59.69
- ABUS $2.71
- Resistance Level
- OPY $61.72
- ABUS $3.73
- Average True Range (ATR)
- OPY 2.12
- ABUS 0.16
- MACD
- OPY 0.50
- ABUS 0.00
- Stochastic Oscillator
- OPY 88.20
- ABUS 32.81
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.